Evidence map›Paper›PMID 37812492›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

OvaPrint-A Cell-free DNA Methylation Liquid Biopsy for the Risk Assessment of High-grade Serous Ovarian Cancer.

David N Buckley, Juan Pablo Lewinger, Gerald Gooden, Monique Spillman, Monica Neuman, X Mona Guo, Ben Yi Tew, Heather Miller, Varun U Khetan, Lee P Shulman and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

David N BuckleyDepartment of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0001-5161-7412
Juan Pablo LewingerDepartment of Population and Public Health Sciences, University of Southern California, Los Angeles, California.ORCID 0000-0002-0692-2570
Gerald GoodenDepartment of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0002-3964-9996
Monique SpillmanDivision of Gynecologic Oncology, Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.ORCID 0009-0001-1127-2672
Monica NeumanDepartment of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0002-8285-7360
X Mona GuoDepartment of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0002-5922-272X
Ben Yi TewDepartment of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0009-0007-6397-7512
Heather MillerDepartment of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0003-1330-7450
Varun U KhetanDepartment of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0003-2825-2157
Lee P ShulmanFeinberg School of Medicine, Northwestern University, Chicago, Illinois.ORCID 0000-0002-4781-0866
Lynda RomanDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Keck School of Medicine of University of Southern California, Los Angeles, California.ORCID 0000-0002-6960-4414
Bodour SalhiaDepartment of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0003-3843-3621
University of Southern California · USNorthwestern University · USWinthrop Rockefeller Foundation · US

Funding

USC Norris Comprehensive Cancer Center (USC Norris) N/AWright Family Foundation (WFF) N/A
6 · The paper itself

Abstract

purposeHigh-grade serous ovarian carcinoma (HGSOC) is the most lethal epithelial ovarian cancer (EOC) and is often diagnosed at late stage. In women with a known pelvic mass, surgery followed by pathologic assessment is the most reliable way to diagnose EOC and there are still no effective screening tools in asymptomatic women. In the current study, we developed a cell-free DNA (cfDNA) methylation liquid biopsy for the risk assessment of early-stage HGSOC. EXPERIMENTAL

designWe performed reduced representation bisulfite sequencing to identify differentially methylated regions (DMR) between HGSOC and normal ovarian and fallopian tube tissue. Next, we performed hybridization probe capture for 1,677 DMRs and constructed a classifier (OvaPrint) on an independent set of cfDNA samples to discriminate HGSOC from benign masses. We also analyzed a series of non-HGSOC EOC, including low-grade and borderline samples to assess the generalizability of OvaPrint. A total of 372 samples (tissue n = 59, plasma n = 313) were analyzed in this study.

resultsOvaPrint achieved a positive predictive value of 95% and a negative predictive value of 88% for discriminating HGSOC from benign masses, surpassing other commercial tests. OvaPrint was less sensitive for non-HGSOC EOC, albeit it may have potential utility for identifying low-grade and borderline tumors with higher malignant potential.

conclusionsOvaPrint is a highly sensitive and specific test that can be used for the risk assessment of HGSOC in symptomatic women. Prospective studies are warranted to validate OvaPrint for HGSOC and further develop it for non-HGSOC EOC histotypes in both symptomatic and asymptomatic women with adnexal masses.

Indexed as

Cell-Free Nucleic AcidsOvarian NeoplasmsCarcinoma, Ovarian EpithelialDNA MethylationFemaleHumansLiquid BiopsyRisk AssessmentCell-Free Nucleic Acids

Identifiers

PMID37812492
PMCPMC10722131
OpenAlexW4387440279

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.